Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease - PubMed (original) (raw)
Review
Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease
Daniel Y Li et al. Semin Nephrol. 2018 Mar.
Abstract
The gut microbiome recently has emerged as a novel risk factor that impacts health and disease. Our gut microbiota can function as an endocrine organ through its unique ability to metabolize various dietary precursors, and can fuel the systemic inflammation observed in chronic disease. This is especially important in the setting of chronic kidney disease, in which microbial metabolism can contribute directly to accumulation of circulating toxins that then can alter and shift the balance of microbiota composition and downstream functions. To study this process, advances in -omics technologies are providing opportunities to understand not only the taxonomy, but also the functional diversity of our microbiome. We also reliably can quantify en masse a wide range of uremic byproducts of microbial metabolism. Herein, we examine the bidirectional relationship between the gut microbiome and the failing kidneys. We describe potential approaches targeting gut microbiota for cardiovascular risk reduction in chronic kidney disease using an illustrative example of a novel gut-generated metabolite, trimethylamine N-oxide.
Keywords: Trimethylamine N-oxide; chronic kidney disease; gut microbiome; uremic toxins.
Copyright © 2018 Elsevier Inc. All rights reserved.
Figures
Figure 1
Dietary precursors are modified by the microbiota to generate an array of uremic toxins through multiple mechanisms at the level of the microbiota, intestinal wall, and liver. Influx of uremic toxins results in microbiota imbalance along with bacterial translocation and inflammation. These factors contribute to the multitude of systemic effects covered in this review.
Figure 2
Overview of TMAO metabolism. Dietary precursors such as red meat, fish, and eggs contain compounds that contain the TMA moiety which is released as TMA, absorbed into circulation and converted to TMAO in the liver. Circulating TMAO has been implicated in processes such as atherosclerosis, platelet activation as well as vascular inflammation. These processes contribute to the development of renal dysfunction. Destruction of tubular secretion mechanisms result in the accumulation of TMAO in the disease setting and contribute to a feed-forward cycle. Modified from Tomlinson et al. 2017.
Similar articles
- Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
Prokopienko AJ, Nolin TD. Prokopienko AJ, et al. Expert Rev Clin Pharmacol. 2018 Jan;11(1):71-82. doi: 10.1080/17512433.2018.1378095. Epub 2017 Sep 20. Expert Rev Clin Pharmacol. 2018. PMID: 28905671 Free PMC article. Review. - The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.
Felizardo RJF, Watanabe IKM, Dardi P, Rossoni LV, Câmara NOS. Felizardo RJF, et al. Pharmacol Res. 2019 Mar;141:366-377. doi: 10.1016/j.phrs.2019.01.019. Epub 2019 Jan 10. Pharmacol Res. 2019. PMID: 30639376 Review. - Diet and Gut Microbiota in Health and Disease.
Shen TD. Shen TD. Nestle Nutr Inst Workshop Ser. 2017;88:117-126. doi: 10.1159/000455220. Epub 2017 Mar 27. Nestle Nutr Inst Workshop Ser. 2017. PMID: 28346928 Review. - Interaction between gut microbiome and cardiovascular disease.
Peng J, Xiao X, Hu M, Zhang X. Peng J, et al. Life Sci. 2018 Dec 1;214:153-157. doi: 10.1016/j.lfs.2018.10.063. Epub 2018 Oct 29. Life Sci. 2018. PMID: 30385177 Review. - Impact of Altered Intestinal Microbiota on Chronic Kidney Disease Progression.
Castillo-Rodriguez E, Fernandez-Prado R, Esteras R, Perez-Gomez MV, Gracia-Iguacel C, Fernandez-Fernandez B, Kanbay M, Tejedor A, Lazaro A, Ruiz-Ortega M, Gonzalez-Parra E, Sanz AB, Ortiz A, Sanchez-Niño MD. Castillo-Rodriguez E, et al. Toxins (Basel). 2018 Jul 19;10(7):300. doi: 10.3390/toxins10070300. Toxins (Basel). 2018. PMID: 30029499 Free PMC article. Review.
Cited by
- Gut Microbiota and Metabolic Alterations Associated with Heart Failure and Coronary Artery Disease.
Yafarova AA, Dementeva EV, Zlobovskaya OA, Sheptulina AF, Lopatukhina EV, Timofeev YS, Glazunova EV, Lyundup AV, Doludin YV, Kiselev AR, Shipulin GA, Makarov VV, Drapkina OM, Yudin SM. Yafarova AA, et al. Int J Mol Sci. 2024 Oct 20;25(20):11295. doi: 10.3390/ijms252011295. Int J Mol Sci. 2024. PMID: 39457077 Free PMC article. - Causal effects of plasma metabolites on chronic kidney diseases and renal function: a bidirectional Mendelian randomization study.
Zhao X, Gao J, Kou K, Wang X, Gao X, Wang Y, Zhou H, Li F. Zhao X, et al. Front Endocrinol (Lausanne). 2024 Jul 26;15:1429159. doi: 10.3389/fendo.2024.1429159. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39129920 Free PMC article. - Commensal microbiome and gastrointestinal mucosal immunity: Harmony and conflict with our closest neighbor.
Tian K, Jing D, Lan J, Lv M, Wang T. Tian K, et al. Immun Inflamm Dis. 2024 Jul;12(7):e1316. doi: 10.1002/iid3.1316. Immun Inflamm Dis. 2024. PMID: 39023417 Free PMC article. Review. - Oral Cardiac Drug-Gut Microbiota Interaction in Chronic Heart Failure Patients: An Emerging Association.
Paraskevaidis I, Briasoulis A, Tsougos E. Paraskevaidis I, et al. Int J Mol Sci. 2024 Jan 31;25(3):1716. doi: 10.3390/ijms25031716. Int J Mol Sci. 2024. PMID: 38338995 Free PMC article. Review. - From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge.
Zhang J, Zhu P, Li S, Gao Y, Xing Y. Zhang J, et al. Front Pharmacol. 2023 Nov 21;14:1291922. doi: 10.3389/fphar.2023.1291922. eCollection 2023. Front Pharmacol. 2023. PMID: 38074146 Free PMC article. Review.
References
- Peitzman SJ. In: Chronic Renal Disease. P Kimmel MR, editor. Elsevier Inc; 2014.
- Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation. 2016;133:518–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P20 HL113452/HL/NHLBI NIH HHS/United States
- R01 DK106000/DK/NIDDK NIH HHS/United States
- R01 HL103931/HL/NHLBI NIH HHS/United States
- R01 HL126827/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials